Michael A. Nauck MDHead of Clinical Trials, Diabetes, Katholisches Klinikum gGmbH, St. Josef Hospital Bochum, Ruhr-University Bochum, Bochum, Germany
Michael Nauck is Head of Clinical Research at the Diabetes Division of St. Josef-Hospital (Ruhr-University Bochum) in Bochum, Germany. He teaches at Georg-August University, Göttingen, and Ruhr-University, Bochum, both in Germany.
Professor Nauck has a particular research interest in the role of gastrointestinal peptide hormones (incretins: glucose-dependent insulinotropic polypeptide, GIP, and glucagon-like peptide-1, GLP-1) in the physiological regulation of metabolism and in the pathophysiology of type 2 diabetes. He has contributed pivotal studies proving a therapeutic potential of GLP-1 in type 2 diabetes. He has contributed to the development of incretin-based glucose-lowering medications such as GLP-1 receptor agonists and inhibitors of dipeptidyl peptidase-4. Additional areas of interest include spontaneous hypoglycaemia (insulinomas), pancreas transplantation, cardiovascular complications of type 2 diabetes, and the modification of cardiovascular risk in type 2-diabetic patients with glucose-lowering pharmacotherapy. His scientific contributions have been honoured with several awards, including the Ferdinand-Bertram Award (1993), the Werner-Creutzfeldt Award (2007) and the Paul Langerhans Medal (2012) of the German Diabetes Association.
Professor Nauck is member of a number of professional societies, including the German, European, American Diabetes Associations, and the International Diabetes Federation. He has served as reviewer for all major diabetes journals and has published more than 200 original articles and 145 reviews and book chapters.
DisclosuresDr, Nauck has been member on advisory boards or has consulted with AstraZeneca, Eli Lilly & Co., Fractyl, GlaxoSmithKline, Menarini/Berlin Chemie, Merck, Sharp & Dohme, and NovoNordisk. He has received grant support from Eli Lilly & Co., Menarini/Berlin-Chemie, Merck, Sharp & Dohme, and Novartis Pharma. He has also served on the speakers bureau of AstraZeneca, Boehringer Ingelheim, Eli Lilly & Co., GlaxoSmithKline, Menarini/Berlin Chemie, Merck, Sharp & Dohme, NovoNordisk, and Sun Pharma.
Recent Contributions to PracticeUpdate:
- Physiological Roles of Incretin Hormones and Their Receptors and Effects of Tirzepatide
- Association of Acute Cholecystitis With the Use of GLP-1 Receptor Agonists
- Effects of Tirzepatide in Type 2 Diabetes
- Lixisenatide Reduces Postprandial Glucose in Patients With Diabetes Secondary to Total Pancreatectomy
- Incretin-Based Drugs and Risk of Cholangiocarcinoma Among Patients With Type 2 Diabetes